Overview

Major advances in external beam radiation therapy in the last decade have provided technologies for planning and delivering highly conformal radiation dose distributions made available by refined beam targeting methods, including intensity‐modulated radiation therapy using tomotherapy, volumetric‐modulated arc therapy and many other auspicious tools for three‐dimensional (3D) dose painting. The emergence of magnetic resonance imaging (MRI) systems integrated with linear accelerators (linacs), commonly known as an MR‐linacs, has realized MR image‐guided radiation therapy (MRgRT) systems. Such progress in technology imposes in turn additional constraints on quality assurance procedures for verifying that the delivered dose to the patient matches the planned dose distribution. In this regard, the advantages of gel dosimetry compared to conventional quality assurance dosimetry systems on MR‐linacs are being debated within the medical physics community. While some think that gel dosimetry provides the optimal end‐to‐end quality assurance dosimetry for MR‐linacs, others think that the technology is still technically challenging and not sufficiently developed in radiation oncology centers for wide adoption in clinical routine. This is the topic addressed in this month's Point/Counterpoint debate.

Arguing for the proposition is Clive Baldock, Ph.D. Dr. Baldock received his Ph.D. from King's College, London, with research undertaken in the field of gel dosimetry for improved 3D radiation therapy dosimetry. He subsequently moved to Queensland University of Technology, Brisbane, Australia in 1997 in the Centre for Medical, Health and Environmental Physics. In 2003, he moved to the University of Sydney as the Director of the Institute of Medical Physics and later as Head of the School of Physics. In 2012, he was appointed the Executive Dean of Science at Macquarie University, Sydney. In 2014, he joined the University of Tasmania as Deputy Dean of the Faculty of Science, Engineering and Technology followed in 2016 by his appointment as the Pro Vice‐Chancellor for Research Development and Dean of Graduate Research. His research interests continue to be in the fields of gel dosimetry, radiation therapy, dosimetry, and medical imaging in which he has published over 150 research journal papers. He has been awarded the Fellowship status by the Australian Institute of Physics, the Australasian College of Physical Scientists and Engineers in Medicine, the Institute of Physics (UK), and the Institute of Physics and Engineering in Medicine (UK).

Arguing against the proposition is Christian P Karger, Ph.D. Dr. Karger has been affiliated with the German Cancer Research Center (DKFZ) since 1993 and obtained his Ph.D. in Physics from the University of Heidelberg (Germany) in 1996. As a certified medical physicist, he participated in the clinical operation of the GSI heavy ion therapy research project from the very beginning, and since 2004, Dr. Karger has headed a research group in DKFZ’s Dept. of Medical Physics in Radiation Oncology. His research activities focus on ion beam and MR‐guided radiotherapy, dosimetry, experimental radiobiology, as well as radiobiological modeling, where he serves as PI of various research projects. In 2007, he became an Associate Professor of Medical Physics at the Medical Faculty at the Heidelberg University. Dr. Karger published more than 100 peer‐reviewed papers and acts as a reviewer for many international journals. Dr. Karger co‐edited a textbook on medical physics and for more than two decades, has participated in several educational medical physics programs as coordinator and lecturer.

中文翻译：

---

凝胶剂量测定为 MR-linac 提供了最佳的端到端质量保证剂量测定。

概述

过去十年外束放射治疗的重大进展为规划和提供高度适形的放射剂量分布提供了技术，这些技术可以通过改进的束靶向方法获得，包括使用断层放射疗法、体积调制弧形疗法和许多其他吉祥工具的强度调制放射疗法用于三维 (3D) 剂量绘制。与直线加速器（linacs）集成的磁共振成像（MRI）系统的出现，俗称MR-linacs，实现了MR图像引导放射治疗（MRgRT）系统。这种技术进步反过来又对质量保证程序施加了额外的限制，以验证向患者提供的剂量是否与计划的剂量分布相匹配。在这方面，与传统的质量保证剂量测定系统相比，凝胶剂量测定在 MR-linac 上的优势正在医学物理学界争论不休。虽然有些人认为凝胶剂量测定为 MR-linac 提供了最佳的端到端质量保证剂量测定，但其他人认为该技术在技术上仍然具有挑战性，并且在放射肿瘤学中心没有得到充分发展，无法在临床常规中广泛采用。这是本月的观点/反点辩论中讨论的主题。其他人则认为该技术在技术上仍然具有挑战性，并且在放射肿瘤学中心尚未充分开发以广泛应用于临床常规。这是本月的观点/反点辩论中讨论的主题。其他人则认为该技术在技术上仍然具有挑战性，并且在放射肿瘤学中心尚未充分开发以广泛应用于临床常规。这是本月的观点/反点辩论中讨论的主题。

支持该提议的是 Clive Baldock 博士。Baldock 博士获得了博士学位。来自伦敦国王学院，在凝胶剂量学领域进行了研究，以改进 3D 放射治疗剂量学。随后，他于 1997 年移居澳大利亚布里斯班昆士兰科技大学医学、健康和环境物理中心。2003年，他移居悉尼大学担任医学物理研究所所长，后来担任物理学院院长。2012 年，他被任命为悉尼麦考瑞大学科学执行院长。2014 年，他加入塔斯马尼亚大学，担任科学、工程和技术学院副院长，并于 2016 年被任命为研究发展副校长和研究生研究院长。他的研究兴趣继续集中在凝胶剂量学、放射治疗、剂量学和医学成像领域，他在这些领域发表了 150 多篇研究期刊论文。他获得了澳大利亚物理研究所、澳大利亚物理科学家和医学工程师学院、物理研究所（英国）和医学物理与工程研究所（英国）授予的奖学金。

反对该提议的是 Christian P Karger 博士。Karger 博士自 1993 年以来一直隶属于德国癌症研究中心 (DKFZ)，并获得了博士学位。1996年获得海德堡大学（德国）物理学博士学位。作为注册医学物理学家，他从一开始就参与了GSI重离子治疗研究项目的临床操作，自2004年以来，Karger博士领导了一个研究小组在 DKFZ 的放射肿瘤学医学物理系。他的研究活动集中在离子束和 MR 引导的放射治疗、剂量学、实验放射生物学以及放射生物学建模方面，他在这些领域担任各种研究项目的 PI。2007年，他成为海德堡大学医学院医学物理学副教授。博士。Karger 发表了 100 多篇同行评审论文，并担任许多国际期刊的审稿人。Karger 博士与他人共同编辑了医学物理学教科书，二十多年来，他作为协调员和讲师参与了多个教育医学物理学项目。